Fischer receives FDA warning letter

Article

Fischer Imaging of Denver received a warning letter from the Food and Drug Administration last month for deficiencies in its manufacturing documentation processes. The notification is the second time in two years that Fischer has received a warning

Fischer Imaging of Denver received a warning letter from the Food and Drug Administration last month for deficiencies in its manufacturing documentation processes. The notification is the second time in two years that Fischer has received a warning letter from the agency (SCAN 5/10/95).

The warning letter follows a six-week FDA inspection that took place late last year as part of a routine biennial audit of Fischer's manufacturing facility, according to Sammy Emrich, director of regulatory affairs at Fischer. In the letter, the FDA expressed concern with manufacturing documentation, as well as the methods Fischer uses to determine trends in its manufacturing process.

Fischer is responding to the letter by improving its documentation processes, examining better system reporting, and establishing product improvement teams, Emrich said. The FDA did not find fault with Fischer's products or the manufacturing process itself, she said.

In the warning letter Fischer received two years ago, the FDA cited Fischer for improper follow-up on repairs, inadequate analysis of product failures, and assigning to a single employee both quality assurance and manufacturing functions. Fischer complied with FDA concerns in that case, and the most recent letter commented on some of the improvements Fischer made in response to the first letter.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.